Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
25 and 50 mg diclofenac K film coated immediate release tablets More
Using a lamellar structure as a delivery system, the Sulidin® Nimesulide LPS gel provides enhanced percutaneous penetration of Nimesulide and reduced yellow staining on the skin. LPS Technology worldwide patents are pending. More
The First Line of Therapy in Severe Migraine Attacks More
Diclofenac transdermal delivery system for the treatment of inflammatory and painful conditions More
25mg dosage strenght for the OTC market in film coated tablets More
Adhesive Patch of 90 sq. cm. and containing as active ingredient 100 mg. of ketoprofen for the local treatment of traumatic injuries and extra-articular rheumatism More
This invention relates to methods for manipulating the immune system using small interfering RNA (siRNA). Potential applications include the development of organ storage/reperfusion solutions and treatments for a broad range of disease indications. More
25mg dosage strenght for the OTC market More
p38 MAP Kinase inhibitors as modulators of pro-inflammatory cytokine-expression for treatment of inflammation-related diseases like rheumatoid arthritis, inflammatory bowel disease, psoriasis, or acute coronary syndrome. More
FMC Pharma is devoted to the treatment of osteoarthritis through the development of products, marketing methodologies and out-licensing opportunities. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us